论文部分内容阅读
３４例有症状的子宫肌瘤患者，在月经来潮的第一天或第二天开始，每天肌注ＧｎＲＨ－Ａ２００ｕｇ或５００ｕｇ，共三个月．结果：Ｂ超检查子宫的平均体积从２０５．３９±２３５．２８ｃｍ３下降为１２５．０６±７３．３９ｃｍ３，缩小４６％（Ｐ＜０．０５）；肌瘤平均体积从５８．１５±６０．７９ｃｍ３减至２９．４４±３９．１１ｃｍ３，缩小４９％（Ｐ＜０．０５）．血清Ｅ２浓度从６１１．０２±２６８．１６ｕｍｏｌ／Ｌ，下降至３０９．００±２１１．３０ｐｍｏｌ／Ｌ（Ｐ＜０．０５）．Ｅ２水平的降低与子宫肌瘤的缩小相一致。同时临床症状明显改善。５例原发不育者，治疗后２例妊娠．１例围绝经期病人用药后诱使绝经，但其余病例在停药后复发．故认为ＧｎＲＨ－Ａ对治疗围绝经和伴不育的子宫肌瘤患者为好．
Thirty-four patients with symptomatic uterine fibroids started either daily with or without GnRH-A 200ug or 500ug daily for three months starting on the first or second day of menstrual flow. Results: The average size of the uterus in B ultrasound examination decreased from 205.39 ± 235.28cm3 to 125.06 ± 73.39cm3, 46% smaller (P <0.05). The average volume of fibroids was 58.15 ± 60.79cm3 Reduced to 29.44 ± 39.11cm3, reduced by 49% (P <0.05). Serum E2 concentration decreased from 611.02 ± 268.16umol / L to 309.00 ± 211.30pmol / L (P <0.05). The reduction of E2 level is consistent with the reduction of uterine fibroids. At the same time significantly improved clinical symptoms. 5 cases of primary infertility, 2 cases of pregnancy after treatment. One patient perimenopausal patients induced postmenopausal medication, but the rest of the cases relapsed after stopping. Therefore, GnRH-A treatment of perimenopausal and infertility patients with uterine fibroids as well.